This debate arose from the fact that the administration of TNF-α inhibitors as treatment for AS may trigger severe side effects, including central and peripheral demyelination disorders, due to the loss or decreased neuronal protection physiologically ensured by TNF-α activation [21]; however, ALS may also occur in AS patients with no history of biological treatments [22]. The gene discussed is TNF; the disease is amyotrophic lateral sclerosis.